Nanobots Contamination of over-the-counter (OTC) Drugs

Nanobots Contamination of over-the-counter (OTC) Drugs

Topics on this Page


Update on FDA’s Investigation

FDA’s Executive Office Warnings/AdvisoriesIntroduction

September 12, 2008: In light of recent evidence from the National Security Agency (NSA), concerning over-the-counter (OTC) Drugs contaminated with nanobots, the FDA has issued a Health Information Advisory to proactively reassure the Office of the President that there is no known health threat from contaminated OTC Drugs manufactured by companies that have met the requirements to sell such products in the United States. Nanobot contamination, if present, poses no apparent risk to health, even to children; however, there may be a risk to privacy.

The nanobots were discovered by NSA because they appear to be activated by an external radio frequency (RF) signal and in response emanate a coded signal. They were found to be less than 1 centimeter long and apparently contain a passive RFID device in addition to a rudimentary mechanism for sensing and memory retention. So far, neither NSA nor FDA has been able to decipher the coded signal. Although this is considerable smaller than the Verichip developed by Kevin Warwick, it is well within the current technology.

These nanites have been found embedded in the center of OTC drugs that come in 325 mgs and larger solid pill form. Contaminated pills range from a low of 1% to a high of 3% of all pills sampled. This is an unusually high level but the method of insertion of these contaminated pills into the manufacturing process of multiple producers has not been determined yet.

Analysis of their exact nature has been complicated by the fact that they seem to be encased with a protective coating that is also highly reactive to light. If a contaminated OTC pill is broken open and the nanite is exposed to light, it immediately disintegrates. Further studies are underway.

The FDA had no knowledge of the presence of these nanobots prior to the notification by NSA in August 2008 and has been hampered in its analysis by a total lack of cooperation from the NSA, however, with NSA’s help, we have been able to determine that in most urban centers, the level of contaminated adults is approximately one in four with slightly greater percentages found in the larger urban centers of New York, Boston, Miami and Dallas.

For some people that take OTC drugs on a regular basis (more than 2 a week), it is possible that they might accumulate more than one nanobot in their system. This does not appear to increase or decrease the health risk to the person but does appear to alter the RF signals emanating from the RFID circuits of the nanites.

The FDA has broadened its domestic and import sampling and testing of OTC drugs from suspected sources but has been unable to define the exact source or sources. FDA has recommended that consumers not consume certain products because of possible contamination with Nanobots. A list of those products is below.

Update on FDA’s InvestigationFebruary 19, 2009: FDA’s ongoing investigation continues to show that the domestic supply of over-the-counter (OTC) Drugs is safe and that consumers can continue using U.S. manufactured OTC Drugs. FDA has concluded that levels of Nanobots alone are at or below 1 pill per thousand (ppt) among all OTC Drugs. This level does not raise public health concerns. FDA has updated its interim risk assessment, issued in early October, with this information:

The FDA has been collecting and analyzing samples of domestically manufactured OTC Drugs for the presence of Nanobots and Nanobots-related RF signal responses. To date, FDA tests have found extremely low levels of Nanobots in one OTC Drugs sample and moderate levels of RF signal responses from concentrations of OTC drugs, such as in a commercial drug store. The benign nature of the nanobots found so far indicate they were designed for tagging, tracking and collection of health information and do not interact with the body or its system and therefore pose no health risk to the public.

To date, statistical data on those individuals that have been contaminated with the nanobots has been limited but several trends have begun to emerge. The number of people contaminated seems to be equally divided among men and women and in a proportional distribution among ethnic and racial groups. The passive RFID tag is responsive to various frequencies in the high UHF and SHF range (922 MHz to 2202 GHz) and appears to makes use of the backscatter coupling method, however, a few known contamination’s could not be activated with any signal source.

Studies have shown that these passive RFID tags can be activated by signals from satellites but have to be read by a receiver located within ten feet. During the testing of nanobots that were actually ingested by people, it was discovered by NSA that the cell phones of the people being tested emanated an unusual signal pattern in response to a band sweep of SHF RF signals. The cell phone activation is being further investigated.

For unknown reasons, some people eliminate or pass their nanobot out of their systems relatively quickly and other people retain the nanobots for either extended periods or permanently (until surgically removed). Further studies are trying to determine what, if any health condition is common among those that retain their nanites. In our sampling of US cities using roaming teams with sweep generators and receivers, it was discovered that the signal being emanated from the RFID tags lasted about 21.7 milliseconds longer than in any other urban center.

As of this FDA Warning, there appears to be no immediate health risk and no reason to unduly alarm the general public with a general public announcement. NSA has indicated they will separately report to the Executive Office of the President on their findings.

Transcript for FDA’s Executive Office Briefing: FDA’s Updated Interim Safety and Risk Assessment of Nanobots and its Analogues in OTC drugs for Humans

November 28, 2008

FDA’s Warnings/Advisories

Recalls Home Page

FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy |

FDA Website Management Staff

Leave a Reply